Molecular Prognostic Markers in Pancreatic Cancer
نویسندگان
چکیده
منابع مشابه
Molecular prognostic markers in pancreatic cancer.
BACKGROUND Pancreatic cancer is one of the most aggressive human tumors and is virtually incurable. Its incidence in the United States has tripled in the past 50 years. The tumor is a frequent cause of cancer death in both men and women. The current treatment options are inadequate and probably reflect the fact that the etiologic factors and the pathogenesis of pancreatic cancer are unknown. ...
متن کاملPrognostic Tumour Markers in Pancreatic Cancer
Academic Dissertation To be presented for public examination with the permission of This thesis is based on the following original publications, which are referred to in the text by their Roman numerals I-V. Loss of p27 expression is associated with poor prognosis in stage I-II pancreatic cancer. Syndecan-1 expression – a novel prognostic marker in pancreatic cancer. Tenascin C expression is up...
متن کاملPrognostic molecular markers in hepatocellular carcinoma (Review article
Hepatocellular carcinoma (HCC) is the 5th commonest malignancy worldwide and is the third most common cause of cancer-related death. The prevalence is different in the world. The ability to predict patients at higher risk of recurrence and with a poor prognosis would help to guide surgical and chemotherapeutic treatment according to individual risk. As understanding of hepatocarcinogenesi...
متن کاملMolecular Prognostic and Predictive Markers in Lung Cancer
Lung cancer is the most common type of cancer in the Western World and there has been systematic effort to find markers with prognostic and predictive significance. Molecular biology is lately being used in order to find markers that are highly sensitive, specific and associated with survival. This review presents recent data regarding the numerous studies that have been conducted in this field...
متن کاملMolecular Markers with Predictive and Prognostic Relevance in Lung Cancer
Lung cancer accounts for the majority of cancer-related deaths worldwide of which non-small-cell lung carcinoma alone takes a toll of around 85%. Platinum-based therapy is the stronghold for lung cancer at present. The discovery of various molecular alterations that underlie lung cancer has contributed to the development of specifically targeted therapies employing specific mutation inhibitors....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Control
سال: 2000
ISSN: 1073-2748,1073-2748
DOI: 10.1177/107327480000700504